Gastroparesis Market Scope And Analysis

  • Report Code : TIPRE00008992
  • Category : Pharmaceuticals
  • No. of Pages : 150
Buy Now

Gastroparesis Market Scope and Analysis Report by 2031

Buy Now

Gastroparesis Market Report Gastroparesis Market Size and Share Gastroparesis Market Scope and Analysis

Gastroparesis Market Report Scope

Report Attribute Details
Market size in 2023 US$ 5.03 billion
Market Size by 2031 US$ 7.39 billion
Global CAGR (2023 - 2031) 4.9%
Historical Data 2021-2022
Forecast period 2023-2031
Segments Covered By Type
  • Idiopathic
  • Diabetic
  • Post-Surgical
By Drug Class Type
  • Prokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin Injection
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • EVOKE PHARMA
  • Bausch Health Companies Inc Salix Pharmaceuticals Ltd
  • Johnson And Johnson Services Inc
  • Allergan Plc
  • NEUROGASTRX INC
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Pfizer Inc
  • ANI Pharmaceuticals Inc
  • Ipca Laboratories Ltd
  • Cinrx Pharma LLC Cindome Pharma

    • Gastroparesis Market News and Recent Developments

    The Gastroparesis Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for gastroparesis and strategies:

    • The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tradipitant for the treatment of gastroparesis. (Source: Vanda Pharmaceuticals, Press Release/Newsletter, 2023)
    • The company treated the first participant with its potential best-in-class pan-GI prokinetic, naronapride, in Europe in a Phase IIb trial to treat gastroparesis. (Source: Renexxion Ireland, Press Release/Company Website/Newsletter, 2023)

    Gastroparesis Market Report Coverage and Deliverables

    The “Gastroparesis Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Market dynamics such as drivers, restraints, and key opportunities
    • Key future trends
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
    • Detailed company profiles